Photodynamic Therapy Using a New Folate Receptor-Targeted Photosensitizer on Peritoneal Ovarian Cancer Cells Induces the Release of Extracellular Vesicles with Immunoactivating Properties.

extracellular vesicles folate-coupled photosensitizer ovarian carcinosis photodynamic therapy

Journal

Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588

Informations de publication

Date de publication:
21 Apr 2020
Historique:
received: 29 01 2020
revised: 11 04 2020
accepted: 12 04 2020
entrez: 25 4 2020
pubmed: 25 4 2020
medline: 25 4 2020
Statut: epublish

Résumé

Often discovered at an advanced stage, ovarian cancer progresses to peritoneal carcinoma, which corresponds to the invasion of the serosa by multiple tumor implants. The current treatment is based on the combination of chemotherapy and tumor cytoreduction surgery. Despite the progress and standardization of surgical techniques combined with effective chemotherapy, post-treatment recurrences affect more than 60% of women in remission. Photodynamic therapy (PDT) has been particularly indicated for the treatment of superficial lesions on large surfaces and appears to be a relevant candidate for the treatment of microscopic intraperitoneal lesions and non-visible lesions. However, the impact of this therapy on immune cells remains unclear. Hence, the objective of this study is to validate the efficacy of a new photosensitizer [pyropheophorbide a-polyethylene glycol-folic acid (PS)] on human ovarian cancer cells and to assess the impact of the secretome of PDT-treated cells on human peripheral blood mononuclear cells (PBMC). We show that PS, upon illumination, can induce cell death of different ovarian tumor cells. Furthermore, PDT using this new PS seems to favor activation of the immune response by inducing the secretion of effective cytokines and inhibiting the pro-inflammatory and immunosuppressive ones, as well as releasing extracellular vesicles (EVs) prone to activating immune cells. Finally, we show that PDT can activate CD4+ and CD8+ T cells, resulting in a potential immunostimulating process. The results of this pilot study therefore indicate that PS-PDT treatment may not only be effective in rapidly and directly destroying target tumor cells but also promote the activation of an effective immune response; notably, by EVs. These data thus open up good prospects for the treatment of micrometastases of intraperitoneal ovarian carcinosis which are currently inoperable.

Identifiants

pubmed: 32326210
pii: jcm9041185
doi: 10.3390/jcm9041185
pmc: PMC7230754
pii:
doi:

Types de publication

Journal Article

Langues

eng

Références

Brain Sci. 2020 Jan 31;10(2):
pubmed: 32024010
J Immunol. 2014 Aug 1;193(3):1006-11
pubmed: 25049431
Oncogene. 2000 Sep 28;19(41):4754-63
pubmed: 11032026
Oncotarget. 2016 Jul 26;7(30):47242-47251
pubmed: 27363018
Trends Biotechnol. 2017 Jul;35(7):665-676
pubmed: 28365132
J Photochem Photobiol B. 2017 Sep;174:70-77
pubmed: 28756154
Gynecol Oncol. 2016 Dec;143(3):496-503
pubmed: 27692668
Medicine (Baltimore). 2018 May;97(21):e10864
pubmed: 29794788
Theranostics. 2018 Jul 30;8(16):4279-4294
pubmed: 30214620
Cancer Med. 2018 Oct;7(10):5047-5056
pubmed: 30133163
Nat Med. 2015 Oct;21(10):1128-38
pubmed: 26444637
Photodiagnosis Photodyn Ther. 2018 Mar;21:121-127
pubmed: 29196245
BMC Cancer. 2018 Nov 5;18(1):1065
pubmed: 30396333
Photodiagnosis Photodyn Ther. 2018 Dec;24:342-348
pubmed: 30381259
Expert Rev Clin Immunol. 2017 May;13(5):491-498
pubmed: 27782752
Biomed Res Int. 2013;2013:482160
pubmed: 23509727
Onco Targets Ther. 2015 Apr 07;8:703-11
pubmed: 25897245
Cancer Manag Res. 2018 Dec 05;10:6685-6693
pubmed: 30584363
J Vis Exp. 2018 Aug 17;(138):
pubmed: 30176015
Bioorg Med Chem. 2017 Jan 1;25(1):1-10
pubmed: 27769669
Nat Rev Immunol. 2018 Dec;18(12):773-789
pubmed: 30254251
Mol Carcinog. 2017 Mar;56(3):1164-1181
pubmed: 27787915
Oncol Lett. 2017 Jun;13(6):4933-4938
pubmed: 28588733
Bull Cancer. 2014 Dec;101(12):1109-13
pubmed: 25532689
Nat Genet. 2001 Oct;29(2):117-29
pubmed: 11586292
Vet J. 2018 Mar;233:8-18
pubmed: 29486883
Immunity. 2013 Jul 25;39(1):74-88
pubmed: 23890065
Photodiagnosis Photodyn Ther. 2016 Mar;13:130-138
pubmed: 26200606
Am J Surg Pathol. 2010 Mar;34(3):433-43
pubmed: 20154587
Curr Opin Cell Biol. 2014 Aug;29:116-25
pubmed: 24959705
Int J Gynecol Pathol. 2013 May;32(3):258-68
pubmed: 23518909
J Photochem Photobiol B. 2019 Aug;197:111544
pubmed: 31295716
Nat Immunol. 2015 May;16(5):448-57
pubmed: 25898198
Cancer Cell. 2016 Dec 12;30(6):836-848
pubmed: 27960084
Maturitas. 2014 Feb;77(2):128-36
pubmed: 24380827
Nat Rev Immunol. 2014 May;14(5):282-3
pubmed: 24751953
Photodiagnosis Photodyn Ther. 2019 Dec;28:10-17
pubmed: 31404677
Mol Cancer Res. 2017 Jan;15(1):78-92
pubmed: 27758876
Methods. 2001 Dec;25(4):402-8
pubmed: 11846609
Eur J Cancer. 2013 Apr;49(6):1374-403
pubmed: 23485231
Endocrinology. 2012 Apr;153(4):1593-602
pubmed: 22416079
Front Immunol. 2018 May 04;9:847
pubmed: 29780381
J Natl Cancer Inst. 2014 Dec 12;107(1):363
pubmed: 25505237
Cell. 2016 Oct 6;167(2):397-404.e9
pubmed: 27667683
Nanomedicine. 2018 Apr 7;14(4):1395-1405
pubmed: 29635082

Auteurs

Martha Baydoun (M)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.

Olivier Moralès (O)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.
CNRS UMS 3702, Institut de Biologie de Lille, 59 021 Lille, France.

Céline Frochot (C)

LGRGP, UMR-CNRS 7274, University of Lorraine, 54 001 Nancy, France.

Colombeau Ludovic (C)

LGRGP, UMR-CNRS 7274, University of Lorraine, 54 001 Nancy, France.

Bertrand Leroux (B)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.

Elise Thecua (E)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.

Laurine Ziane (L)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.

Anne Grabarz (A)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.
Unité de Gynécologie-Obstétrique, Hôpital Jeanne de Flandre, 59 000 CHU Lille, France.

Abhishek Kumar (A)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.

Clémentine de Schutter (C)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.

Pierre Collinet (P)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.
Unité de Gynécologie-Obstétrique, Hôpital Jeanne de Flandre, 59 000 CHU Lille, France.

Henri Azais (H)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.
Service de Chirurgie et Cancérologie Gynécologique et Mammaire, Hôpital de la Pitié-Salpêtrière, AP-HP, 75 013 Paris, France.

Serge Mordon (S)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.

Nadira Delhem (N)

Université de Lille, Faculté des Sciences et Technologies, INSERM, CHU-Lille, U1189-ONCO-THAI-Assisted Laser Therapy and Immunotherapy for Oncology, F-59000 Lille, France.

Classifications MeSH